AVXLANAVEX LIFE SCIENCES CORP.

Nasdaq anavex.com


$ 6.30 $ -0.34 (-5.05 %)    

Friday, 09-Aug-2024 15:59:59 EDT
QQQ $ 450.22 $ 2.34 (0.52 %)
DIA $ 395.16 $ 0.63 (0.16 %)
SPY $ 532.81 $ 2.34 (0.44 %)
TLT $ 96.28 $ 0.94 (0.99 %)
GLD $ 224.54 $ 0.55 (0.25 %)
$ 6.305
$ 6.30 x 195
$ 6.32 x 232
-- - --
$ 3.25 - $ 10.45
651,161
na
533M
$ 1.59
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-06-2024 06-30-2024 10-Q
2 05-09-2024 03-31-2024 10-Q
3 02-07-2024 12-31-2023 10-Q
4 11-27-2023 09-30-2023 10-K
5 08-08-2023 06-30-2023 10-Q
6 05-09-2023 03-31-2023 10-Q
7 02-07-2023 12-31-2022 10-Q
8 11-28-2022 09-30-2022 10-K
9 08-09-2022 06-30-2022 10-Q
10 05-10-2022 03-31-2022 10-Q
11 02-09-2022 12-31-2021 10-Q
12 11-24-2021 09-30-2021 10-K
13 08-12-2021 06-30-2021 10-Q
14 05-13-2021 03-31-2021 10-Q
15 02-16-2021 12-31-2020 10-Q
16 12-28-2020 09-30-2020 10-K
17 08-06-2020 06-30-2020 10-Q
18 05-07-2020 03-31-2020 10-Q
19 02-06-2020 12-31-2019 10-Q
20 12-16-2019 09-30-2019 10-K
21 08-07-2019 06-30-2019 10-Q
22 05-09-2019 03-31-2019 10-Q
23 02-07-2019 12-31-2018 10-Q
24 12-12-2018 09-30-2018 10-K
25 08-09-2018 06-30-2018 10-Q
26 05-10-2018 03-31-2018 10-Q
27 02-07-2018 12-31-2017 10-Q
28 12-11-2017 09-30-2017 10-K
29 08-07-2017 06-30-2017 10-Q
30 05-10-2017 03-31-2017 10-Q
31 02-07-2017 12-31-2016 10-Q
32 12-14-2016 09-30-2016 10-K
33 08-11-2016 06-30-2016 10-Q
34 05-11-2016 03-31-2016 10-Q
35 02-08-2016 12-31-2015 10-Q
36 12-29-2015 09-30-2015 10-K
37 08-14-2015 06-30-2015 10-Q
38 05-14-2015 03-31-2015 10-Q
39 02-17-2015 12-31-2014 10-Q
40 12-29-2014 09-30-2014 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 anavex-life-sciences-q3-2024-gaap-eps-014-beats-016-estimate-cash-and-equivalents-of-1388m

Anavex Life Sciences (NASDAQ:AVXL) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of ...

 hc-wainwright--co-reiterates-buy-on-anavex-life-sciences-maintains-40-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Anavex Life Sciences (NASDAQ:AVXL) with a Buy and maintains $4...

 anavex-life-sciences-reported-preclinical-results-in-directly-to-humans-translatable-biomarkers-for-individuals-with-fxs-for-anavex2-73-blarcamesine-in-a-disease-model-of-fragile-x-syndrome-fxs

ANAVEX®2-73 corrects directly to humans' translatable EEG biomarkers in a model of Fragile X Syndrome (FXS). Therapeutic...

 neurodegenerative-disease-focused-anavex-life-sciences-alzheimers-candidate-slows-disease-progression-by-almost-39

Anavex Life Sciences presented Phase 2b/3 study results at AAIC 2024, showing daily oral blarcamesine (ANAVEX2-73) significantl...

 ef-hutton-maintains-buy-on-anavex-life-sciences-maintains-46-price-target

EF Hutton analyst Jason Kolbert maintains Anavex Life Sciences (NASDAQ:AVXL) with a Buy and maintains $46 price target.

 anavex-life-sciences-earlier-announced-oral-once-daily-blarcamesine-significantly-slowed-clinical-decline-for-early-alzheimers-disease-patients-functional-co-primary-endpoint-adcs-adl-was-trending-positive-but-did-not-reach-significance-at-week-48

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing dif...

 ef-hutton-initiates-coverage-on-anavex-life-sciences-with-buy-rating-announces-price-target-of-46

EF Hutton analyst Jason Kolbert initiates coverage on Anavex Life Sciences (NASDAQ:AVXL) with a Buy rating and announces Pri...

 hc-wainwright--co-reiterates-buy-on-anavex-life-sciences-maintains-40-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Anavex Life Sciences (NASDAQ:AVXL) with a Buy and maintains $4...

 hc-wainwright--co-reiterates-buy-on-anavex-life-sciences-maintains-40-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Anavex Life Sciences (NASDAQ:AVXL) with a Buy and maintains $4...

 anavex-life-sciences-q2-2024-gaap-eps-013-misses-011-estimate-cash-and-equivalents-of-1394m

Anavex Life Sciences (NASDAQ:AVXL) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate o...

 anavex-life-sciences-q1-eps-011-beats-014-estimate-cash-and-cash-equivalents-of-1438m

Anavex Life Sciences (NASDAQ:AVXL) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of ...

 earnings-scheduled-for-february-7-2024

Companies Reporting Before The Bell • Madison Square Garden (NYSE:MSGE) is expected to report quarterly loss at $0.80 per shar...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION